Navigation Links
John Theurer Cancer Center first in New Jersey to offer complete capabilities of Provenge
Date:4/4/2011

HACKENSACK, N.J. (April 4, 2011) The John Theurer Cancer Center at Hackensack University Medical is the only cancer center in New Jersey where advanced prostate cancer patients can receive a cell collection process and infusion of Provenge (Sipuleucel-T). Now, patients can find the complete capabilities of this breakthrough immunotherapy in one center led by one physician.

"We are now able to provide patients with care that is not only innovative for improved outcomes, but convenient and more personal," said Robert Alter, M.D., Co-Chief, Urologic Oncology at the John Theurer Cancer Center. "Throughout the Provenge delivery process, patients are treated by a single team of our expert staff, allowing for a more intimate, comforting course of treatment."

Provenge is the first autologous cellular immunotherapy available for the treatment of advanced prostate cancer, meaning it is designed to use cells from a patient's own immune system to identify and target prostate cancer. The John Theurer Cancer Center participated in the Provenge clinical trials, and began prescribing and infusing patients when the treatment was approved in June 2010. This February, the John Theurer Cancer Center received approval by Provenge manufacturer, Dendreon, to conduct leukapheresis, a cell collection process vital for the development of the immunotherapy.

"Provenge is another example of the cutting-edge treatments we provide our patients at the John Theurer Cancer Center," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., Chief Innovations Officer and Professor and Vice President of Cancer Services at the John Theurer Cancer Center. "We strive to deliver patients with the latest treatment options and state-of-the-art technology in order to deliver exceptional care."

Provenge treatment at the John Theurer Cancer Center begins with leukapheresis, a cell collection process administered by a clinical assistant. The patient's cells are sent to a Provenge manufacturing facility, where they are combined with a protein that is found in most prostate cancers linked to an immune stimulating agent. The dose of Provenge is then sent back to the cancer center for infusion. This whole process is performed three times over approximately six weeks for complete treatment.


'/>"/>

Contact: Jaymie DeGaetano
jaymie.degaetano@widmeyer.com
646-213-7243
John Theurer Cancer Center
Source:Eurekalert

Related medicine news :

1. The MMRF and John Theurer Cancer Center to host patient symposium
2. John Theurer Cancer Center orthopedic oncologist shares new limb sparing surgical techniques
3. John Theurer Cancer Center to host Eighth Annual Northern New Jersey Breast Cancer Conference
4. Oncology basic research director at John Theurer Cancer Center continues transplantation research
5. John Theurer Cancer Center presents studies on promising therapies for aggressive blood cancers
6. The John Theurer Cancer Center to unveil 40 presentations at the 52nd ASH Annual Meeting
7. John Theurer Cancer Center to present innovative research at 2 surgical meetings
8. John Theurer Cancer Center first cancer center in N.J. to acquire new radiotherapy system
9. John Theurer Cancer Center and LLS host panel discussion with leading hematologists
10. The John Theurer Cancer Center recognizes medical physics team for safety track record
11. John Theurer Cancer Center experts present new cancer research at ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a ... second affiliate in Latin America . ... ... ... ...
(Date:6/23/2016)... N.J. , June 23, 2016  Guerbet announced ... Premier Inc.,s Supplier Horizon Award . ... year, Guerbet was recognized for its support of Premier ... creation through clinical excellence, and commitment to lower costs. ... to receive this recognition of our outstanding customer service ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Surgical Procedure Volumes: Global Analysis (United States, ... Australia, Canada)" report to their offering. ... an essential tool for healthcare business planners, provides surgical ... looks at surgery trends with an in-depth analysis of ...
Breaking Medicine Technology: